Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 250

Quadrant Biosciences to Collaborate on Signature Study of Minocycline Treatment of Autism Spectrum Disorder

Posted by fidest press agency su sabato, 27 ottobre 2018

Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network (ATN) and its university research partners on research into the treatment of autism spectrum disorder (ASD). The ATN is a collaboration of Autism Speaks and some of the finest children’s hospitals and academic institutions in North America, specializing in multi-disciplinary medical care for children with autism. This Signature Study, including researchers from the Cincinnati Children’s Hospital Medical Center, University of Pittsburgh, and University of Missouri, is looking at the treatment of autism symptoms with the antibiotic minocycline. In addition to providing financial support for this important study, Quadrant Biosciences will be collecting salivary RNA data to further its work on epigenetic factors associated with ASD.Prompted by earlier studies, researchers at the Cincinnati Children’s Hospital Medical Center initiated a study looking at the effects of minocycline treatment on ASD symptoms.
Given these characteristics, animal researchers hypothesized that minocycline treatment would improve autism symptoms, and indeed this was the case. Researchers saw improvement in many classic autism symptoms such as aberrant social interaction, exploratory behavior, locomotion, and anxiety behaviors in various mouse models of ASD treated with minocycline. Additionally, trials in humans with Fragile X Syndrome-associated ASD have demonstrated improvement on the Clinical Global Impression Improvement subscale. These compelling results prompted the initiation of the present Autism Speaks ATN Signature Study.
The Autism Speaks ATN research also received support through the ATN’s role as the federally funded Autism Intervention Research Network for Physical Health. The clinical trial to begin later this year will involve a 24-subject, double-blind, placebo-controlled, four-week crossover study of minocycline in youths with ASD ages 12 to 22 years. The study aims to: 1) Determine if minocycline use will be associated with reduction in elevated EEG gamma power in persons with ASD compared to placebo; 2) assess the short-term safety and tolerability of minocycline in youths with ASD; and 3) better understand the efficacy and dosage of minocycline for the short-term treatment of memory, social gaze, psychophysical markers, attentional impairments, quality of life, and other concerns in adolescents with ASD.
The study includes well-regarded researchers in the autism field including Craig A. Erickson, M.D., Professor, Division of Child and Adolescent Psychiatry, and Logan Wink, Associate Professor, Cincinnati Children’s Hospital Medical Center; David Beversdorf, M.D., Professor of Neurology, Radiology, and Psychology, Thompson Center for Autism & Neurodevelopmental Disorders, University of Missouri; and Benjamin Handen, Ph.D., Professor of Psychiatry, Pediatrics, Psychology, and Education, University of Pittsburgh.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: